Clinical trial
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for…
NCT00328692 · NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00328692 |
|---|---|
| Title | PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous… |
| Lead sponsor | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Collaborators | Merck Sharp & Dohme LLC Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Drug |
| Interventions | rolofylline, Comparator: Placebo (unspecified) |
| Enrollment | 932 |
| Start date | Aug 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | May 22, 2006 |
| Last update posted | Oct 9, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: